Treatment of Acute Lung Injury and Acute Respiratory Distress Syndrome

急性肺损伤和急性呼吸窘迫综合征的治疗

• 批准号: 8844850
• 负责人: Roy G. Brower
• 金额: $ 13.27万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-09-30 至 2014-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8844850
• 关键词: Acute; Acute Lung Injury; Adult; Adult Respiratory Distress Syndrome; Caring; Characteristics; Clinical; Clinical Research; Clinical Trials; Clinical Trials Data Monitoring Committees; Consent Forms; Critical Illness; Edema; Electronics; Eligibility Determination; Enrollment; Ethics; Gender; Hypoxemia; Intensive Care Units; Lung Inflammation; Natural History; Outcome; Pathology; Patients; Pharmaceutical Preparations; Procedures; Protocols documentation; Publications; Research Personnel; Resources; Respiratory distress; Review Committee; Sampling; Syndrome; Teleconferences; Voting; base; data exchange; improved; meetings; member; mortality; patient population; prevent; protocol development

Acute lung injury (ALI) and its more severe form, adult respiratory distress (ARD), is a devastating clinical syndrome of sudden lung inflammation that results in severe edema and hypoxemia and requires care in the intensive care unit. Mortality is between 30-40% in controlled settings. To date, no single drug has proven effective for improving mortality in ALI/ARDS despite many large and small clinical trials. The objective of the Clinical Research Network (ARDSNet) is to develop and conduct clinical research trials to prevent, treat, and improve the outcome of patients with acute lung injury, acute respiratory distress syndrome, and possibly other related critical illnesses. Enroll a minimum of 30 patients per year with ALI/ARDS. Describe in detail the gender and racial characteristics of the patient population. Set priorities for and participate in protocol development, developing specific protocols, determination of subject eligibility criteria, developing procedures for electronic transmission of data, developing sample consent forms. Be voting members of the SC; attend meetings and teleconferences. Participate in one or more of a number of subcommittees (e.g., publications, ethics, pathology, natural history, and progress assessment) which will hold meetings and teleconferences on an as-needed basis. Investigators may be asked to participate in Protocol Review Committee (PRC) and Data and Safety Monitoring Board (DSMB) meetings and teleconferences to serve as a resource.

急性肺损伤（ALI）及其更严重的成人呼吸窘迫（ARD）是一种急性肺部炎症的破坏性临床综合征，导致严重的水肿和低氧血症，需要在重症监护病房中进行护理。在受控设置中，死亡率在30-40％之间。迄今为止，尽管进行了许多大型和小型临床试验，但尚无单一药物可有效提高ALI/ARD的死亡率。临床研究网络（ARDSNET）的目的是开发和进行临床研究试验，以防止，治疗和改善急性肺损伤，急性呼吸窘迫综合征以及可能其他相关危重疾病的患者的结果。 每年至少有30名患者使用ALI/ARDS。详细描述患者群体的性别和种族特征。 为协议制定，制定特定协议，确定受试者资格标准，制定电子传输的程序，开发样本同意书的方法。 成为SC的投票成员；参加会议和电视会议。 参加一个或多个小组委员会（例如出版物，伦理，病理学，自然历史和进步评估）中的一个或多个小组委员会，这些小组委员会将在需要的基础上举行会议和电信。可以要求调查人员参加协议审查委员会（PRC）以及数据与安全监测委员会（DSMB）会议和电信会议，以作为资源。